First Report of 3-Year Clinical Outcome After Treatment With Novel Resolute Onyx Stents in the Randomized BIONYX Trial
Eline H. Ploumen, Rosaly A. Buiten, Paolo Zocca, Carine J.M. Doggen, Adel Aminian, Carl E. Schotborgh, Gillian A.J. Jessurun, Ariel Roguin, Peter W. Danse, Edouard Benit, Clemens von Birgelen
Abstract
BACKGROUND: At 1 year, the international randomized BIONYX trial (ClinicalTrials.gov:NCT02508714) established non-inferiority regarding safety and efficacy of the novel Resolute Onyx zotarolimus-eluting stent (RO-ZES) vs. the Orsiro sirolimus-eluting stent (O-SES). Although the RO-ZES is used in daily practice, no clinical results have been published beyond 2 years. METHODS AND RESULTS: =0.09). CONCLUSIONS: This first 3-year randomized assessment of the RO-ZES showed a favorable rate of TVF that matched the outcomes of patients treated with O-SES. We observed a lower rate of all-cause death in the RO-ZES group, but long-term clinical follow-up is of interest.